TY  - JOUR
AU  - Jones, JA
AU  - Hillmen, P
AU  - Coutre, S
AU  - Tam, C
AU  - Furman, RR
AU  - Barr, PM
AU  - Schuster, SJ
AU  - Kipps, TJ
AU  - Flinn, IW
AU  - Jaeger, U
AU  - Burger, JA
AU  - Cheng, M
AU  - Ninomoto, J
AU  - James, DF
AU  - Byrd, JC
AU  - O'Brien, SM
Y2  - 2021/02/04
Y1  - 2017/07/01
SN  - 0007-1048
UR  - http://hdl.handle.net/11343/259160
AB  - Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.
LA  - English
PB  - WILEY
T1  - Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
DO  - 10.1111/bjh.14660
IS  - British Journal of Haematology
VL  - 178
IS  - 2
SP  - 286-291
L1  - /bitstream/handle/11343/259160/PMC6084297.pdf?sequence=1&isAllowed=y
ER  -